Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141223 |
| CAS No | NA |
| Mol.F. | C25H29F3N4O4 |
| Mol.Wt. | 506.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141224 |
| CAS No | NA |
| Mol.F. | C32H33F3N4O5 |
| Mol.Wt. | 610.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141225 |
| CAS No | NA |
| Mol.F. | C13H22N4OS |
| Mol.Wt. | 282.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141226 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141227 |
| CAS No | NA |
| Mol.F. | C13H22N4OS |
| Mol.Wt. | 282.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141228 |
| CAS No | NA |
| Mol.F. | C13H21N5O2S |
| Mol.Wt. | 311.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141229 |
| CAS No | NA |
| Mol.F. | C20H30N8O2S2 |
| Mol.Wt. | 478.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141230 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141231 |
| CAS No | NA |
| Mol.F. | C10H16N4OS |
| Mol.Wt. | 240.3 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141232 |
| CAS No | NA |
| Mol.F. | C17H13N5O3 |
| Mol.Wt. | 335.3 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141233 |
| CAS No | NA |
| Mol.F. | C9H9N3O2 |
| Mol.Wt. | 191.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141234 |
| CAS No | NA |
| Mol.F. | C28H21F3N8O3 |
| Mol.Wt. | 574.5 |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0141235 |
| CAS No | NA |
| Mol.F. | C26H23N5O5 |
| Mol.Wt. | 485.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141236 |
| CAS No | NA |
| Mol.F. | C27H19F3N8O2 : HCl |
| Mol.Wt. | 544.5 : 36.5 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141237 |
| CAS No | NA |
| Mol.F. | C19H17N5O3 |
| Mol.Wt. | 363.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141238 |
| CAS No | NA |
| Mol.F. | C27H25N5O5 |
| Mol.Wt. | 499.5 |
| INV STATUS | CUSTOM SYNTHESIS |